

# Jeffrey Newcorn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1913587/publications.pdf>

Version: 2024-02-01

23  
papers

1,217  
citations

623734

14  
h-index

752698

20  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1231  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Treatment With Extended-Release Methylphenidate Treatment in Children Aged 4 to <6 Years. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, , .	0.5	8
2	A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). <i>CNS Drugs</i> , 2021, 35, 1035-1051.	5.9	16
3	Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. <i>European Neuropsychopharmacology</i> , 2019, 29, 432-443.	0.7	5
4	A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Methylphenidate in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). <i>CNS Drugs</i> , 2018, 32, 289-301.	5.9	19
5	Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 602-609.e2.	0.5	21
6	Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , 2017, 31, 999-1014.	5.9	33
7	Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised withdrawal maintenance of efficacy study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2016, 57, 717-728.	5.2	26
8	Developmental progression to early adult binge drinking and marijuana use from worsening versus stable trajectories of adolescent attention deficit/hyperactivity disorder and delinquency. <i>Addiction</i> , 2015, 110, 784-795.	3.3	33
9	Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: A pilot fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2015, 231, 353-356.	1.8	9
10	Medication for ADHD and accidental injury. <i>Lancet Psychiatry</i> , the, 2015, 2, 669-671.	7.4	1
11	SNP genotyping using TaqMan® technology: the CYP2D6*17 assay conundrum. <i>Scientific Reports</i> , 2015, 5, 9257.	3.3	24
12	Recent Progress in Psychosocial and Psychopharmacologic Treatments for ADHD. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 14-27.	1.9	1
13	Comorbidity of ADHD and anxiety disorders. , 2014, , 98-110.		5
14	Randomized, Double-Blind Trial of Guanfacine Extended Release in Children With Attention-Deficit/Hyperactivity Disorder: Morning or Evening Administration. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 921-930.	0.5	49
15	Can Children With Callous and Unemotional Traits Be Treated Successfully?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 1257-1259.	0.5	1
16	Dose-Response Characteristics in Adolescents with Attention-Deficit/Hyperactivity Disorder Treated with OROS® Methylphenidate in a 4-Week, Open-Label, Dose-Titration Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 187-196.	1.3	26
17	Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 511-518.	0.5	72
18	Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 1165-1172.	0.5	35

#	ARTICLE	IF	CITATIONS
19	Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response. American Journal of Psychiatry, 2008, 165, 721-730.	7.2	294
20	Low-Dose Atomoxetine for Maintenance Treatment of Attention-Deficit/Hyperactivity Disorder. Pediatrics, 2006, 118, e1701-e1706.	2.1	30
21	Atomoxetine Treatment in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 240-248.	0.5	154
22	Symptom Profiles in Children With ADHD: Effects of Comorbidity and Gender. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 137-146.	0.5	347
23	New treatments and approaches for attention deficit hyperactivity disorder. Current Psychiatry Reports, 2001, 3, 87-91.	4.5	8